It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Tuberculosis (TB) remains a leading cause of death from an infectious disease worldwide, partly due to a lack of effective strategies to screen and triage individuals with potential TB. Whole blood RNA signatures have been tested as biomarkers for TB, but have failed to meet the World Health Organization’s (WHO) optimal target product profiles (TPP). Here, we use RNA sequencing and machine-learning to investigate the utility of plasma cell-free RNA (cfRNA) as a host-response biomarker for TB in cohorts from Uganda, Vietnam and Philippines. We report a 6-gene cfRNA signature, which differentiates TB-positive and TB-negative individuals with AUC = 0.95, 0.92, and 0.95 in test, training and validation, respectively. This signature meets WHO TPPs (sensitivity: 97.1% [95% CI: 80.9-100%], specificity: 85.2% [95% CI: 72.4-100%]) regardless of geographic location, sample collection method and HIV status. Overall, our results identify plasma cfRNA as a promising host response biomarker to diagnose TB.
Whole blood signatures have served as the potential biomarkers for TB but failed to meet World Health Organization’s (WHO) optimal target product profiles (TPP). By employing cohorts from multiple countries, the authors identify a diagnostic 6-gene signature from cell free RNA which outperforms TPP requirement in distinguishing TB from non-TB.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details





1 Cornell University, Meinig School of Biomedical Engineering, Ithaca, USA (GRID:grid.5386.8) (ISNI:0000 0004 1936 877X)
2 Inc., Global Health Labs, Bellevue, USA (GRID:grid.450107.7)
3 World Alliance for Lung and Intensive Care Medicine in Uganda, Kampala, Uganda (GRID:grid.450107.7)
4 National Lung Hospital, Hanoi, Vietnam (GRID:grid.470059.f)
5 De La Salle Medical and Health Sciences Institute, Dasmarinas, Philippines (GRID:grid.470059.f)
6 World Alliance for Lung and Intensive Care Medicine in Uganda, Kampala, Uganda (GRID:grid.470059.f)
7 University Hospital Heidelberg & German Center of Infection Research, Heidelberg, Germany (GRID:grid.5253.1) (ISNI:0000 0001 0328 4908)
8 University of California San Francisco, UCSF Center for Tuberculosis, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811)
9 University of California San Francisco, UCSF Center for Tuberculosis, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811); University of California Irvine, Division of Pulmonary and Critical Care Medicine, Orange, USA (GRID:grid.266093.8) (ISNI:0000 0001 0668 7243)